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Table
G. CSF Pilot Interim Analysis
No G. CSF
Median (Days)
G CSF
Control (Days)
Autologous (7 Cases, 10 Controls)
LOS 15 12
Neutrophil Engraftment 12 10
Allogeneic MAC (BM & PBPC)
(9 Cases, 9 Controls)
LOS 22 17
Neutrophil Engraftment 22 12
Allogeneic RIC (PBPC) (10 Cases,
10 Controls)
LOS 19 17
Neutrophil Engraftment 14 13
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perspective.
Conclusion: While our 30 day readmission rate has
decreased from 34.6 in 2009 to current rate of 23.5 (See
Figure), we still have work to do. The initial reduction cannot
be attributed to any particular effort(s) and we will continue
to be diligent and innovative in this endeavor. Some
readmissions are not preventable and fevers are a big
barrier. In the near future we hope to create a working
group with other institutions, focus on the patients who
are readmitted frequently, and develop criteria to deﬁne
what a true preventable readmission is.
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Introduction: Quality of care is a priority among patients,
providers, and accreditors in blood and marrow trans-
plantation (BMT), and has resulted in the need to develop
quality management systems. BMT programs can apply
quality frameworks such as the Model for Improvement,
which guide programs to set quality goals, and to develop
quality measurement and reporting strategies to ensure
progress toward those goals. We report on the systematic,
end-user-informed development of a set of quality in-
dicators, to be monitored and reported on in the context of a
quality framework at the Princess Margaret Cancer Centre
BMT program.
Methods: This involved three phases: 1) Evidence Review
(database and grey literature search for quality indicators
used in BMT); 2) Modiﬁed Delphi process, inwhich identiﬁed
indicator concepts were discussed to generate a list of broad
clinical categories, then prioritized via a staff survey; and 3)
investigation of the published literature for data standards
for these indicators.
Results: Evidence review generated 214 indicators, which
were categorized as Clinical (n¼139), Management-level
(n¼40), or Hospital-wide (n¼35). Only the Clinical in-
dicators were deemed meaningful for staff prioritization.
By merging like concepts, the 139 indicators were reduced
to 22 for inclusion in the prioritization exercise. Prioriti-
zation was achieved through an online survey sent to 152
clinical BMT staff. Respondents ranked indicators based on
their perceived clinical value as quality measures. Re-
spondents ranked “Survival” and “Treatment-related mor-
tality” most frequently in their top 3 choices. However, a
low survey response rate (35 of 152, or 23%) suggested a
lack of staff awareness of quality measurement, and a need
to coordinate staff education and creation of a quality
improvement culture to ensure success of such initiatives
in the future. Next, Management-level indicators were
pared down through discussion and consensus, generating
12 indicators to be developed for future reporting. The
Hospital-wide indicators, which were non-BMT-speciﬁc
but could be adapted for use in BMT quality measurement,
were mapped to corresponding Management-level and
Clinical indicators. Their existing measurement structures
may be useful in developing measurement strategies for
our BMT-speciﬁc quality indicators. Finally, workingtoward eventual implementation, all indicators were
assessed for any data standards mentioned in the litera-
ture. Our ﬁndings revealed a paucity of published data
standards for BMT quality indicators, highlighting a need
for more research in this ﬁeld.
Conclusions: Quality indicator development in BMT can be
undertaken systematically, but requires a concerted effort
from staff engagement to informatics infrastructure.
Currently, this area is challenged by a lack of published
development standards and implementation studies.123
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Background: The use of granulocyte colony stimulating
factor (G-CSF) to promote engraftment after hematopoietic
cell transplantation (HCT) remains controversial. Random-
ized controlled trials that showed a shorter duration of
neutropenia after G-CSF in autologous (auto) HCT recipients
were performed in an era when present supportive care
resources were not available. The use of G-CSF after allo-
geneic (allo) HCT is not established by randomized trials
and there is a concern that it may be associated with an
increased risk of graft-versus-host disease. G-CSF is a costly
drug and excluding its routine use may translate into sig-
niﬁcant cost savings for a transplant program. All inpatients
transplanted routinely receive G-CSF 480 mcg/day starting
day +5. We conducted a pilot study to evaluate if G-CSF
post-HCT could be safely omitted after autologous and
allogeneic HCT.
Methods: 2013 data was used as benchmarks for neutrophil
engraftment and hospital length of stay (LOS), calculated
from day 0. Three separate pilots were conducted for auto
HCT, myeloablative (MAC) allo and reduced-intensity (RIC)
allo HCT recipients. Eligibility criteria included sufﬁcient cell
dose for the product to be infused (PBSC 5.0 x106 CD34+
cells/kg for autos,2.0 x106/kg for allos or BM2.0x108 TNC/
kg). G-CSF was not administered prophylactically, but could
be given in clinical scenarios such as prolonged febrile
